Clinical Trial

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-11.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT07122076
Lead Sponsor Grit Biotechnology
Conditions Autoimmune Diseases
Enrollment 10 participants
Start Date 2025-08-22
Primary Completion 2028-08-21 (estimated)
Study Completion 2028-08-21 (estimated)
Updated on ClinicalTrials.gov 2025-09-22